PRESENT
hair loss, fatigue, loss of taste
HAIR LOSS, LOSS OF APPETITE
The present study showed that all predefined PROs were comparable between both groups (i.e., no statistically significant differences) and all returned to baseline at 3 or 6 months postoperatively. Secondary explorative analyses in patients receiving perioperative systemic therapy showed statistically significant and clinically relevant worsening of several PROs (fatigue, hair loss, loss of taste, and loss of appetite) following neoadjuvant treatment. However, all of these (except loss of appetite) returned to baseline scores at 3 or 6 months after CRS/HIPEC.